{"created":"2023-05-15T09:06:17.706423+00:00","id":12935,"links":{},"metadata":{"_buckets":{"deposit":"19c9b934-0285-40b7-a27c-2bc77fa6f946"},"_deposit":{"created_by":14,"id":"12935","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"12935"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00012935","sets":["1875:1978:1986"]},"author_link":["19164"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-10-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"16","bibliographicPageStart":"13","bibliographicVolumeNumber":"72","bibliographic_titles":[{"bibliographic_title":"市立札幌病院医誌 = Acta medica nosocomi Sapporo = The Journal of Sapporo City General Hospital"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"1990年代までは大腸癌に対する化学療法は5-FUにLeucovorinを併用する5-FU+LV療法が標準的であったがirinotecan (CPT-11)、oxaliplatin (1-OHP)といった新規抗がん剤の開発に加え、bavacizumab (Bev)、cetuximab (Cmab)、panitumumab (Pmab)などの分子標的治療薬が登場することでその治療成績は飛躍的に向上した。NCCNガイドラインおよび本邦の大腸癌治療ガイドラインでも切除不能進行・再発大腸癌の1次治療においてこれらの分子標的薬の併用が推奨されている。ここではそれぞれの薬剤に関する治療成績などについてまとめることとする。","subitem_description_type":"Abstract"}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"市立札幌病院"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0288-6073","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"中村, 路夫"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-21"}],"displaytype":"detail","filename":"l425672113.pdf","filesize":[{"value":"945.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"l425672113.pdf","url":"https://sapmed.repo.nii.ac.jp/record/12935/files/l425672113.pdf"},"version_id":"c07d1e6c-4431-4bee-9472-8be05fcf0428"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"大腸癌における分子標的薬治療(特集分子標的薬を用いた治療戦略)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"大腸癌における分子標的薬治療(特集分子標的薬を用いた治療戦略)","subitem_title_language":"ja"}]},"item_type_id":"2","owner":"14","path":["1986"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2014-05-15"},"publish_date":"2014-05-15","publish_status":"0","recid":"12935","relation_version_is_last":true,"title":["大腸癌における分子標的薬治療(特集分子標的薬を用いた治療戦略)"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-12-13T04:30:16.766013+00:00"}